Health Care & Life Sciences » Biotechnology | bioMmune Technologies Inc.

bioMmune Technologies Inc. | Income Statement

Fiscal year is December-November. All values CAD Thousands.
2015
2016
2017
2018
Cost of Goods Sold (COGS) incl. D&A
86.70
87.00
93.10
98.50
Gross Income
86.70
87.00
93.10
98.50
SG&A Expense
994.20
1,381.70
1,499.50
2,492
EBIT
1,080.90
1,468.70
1,592.60
2,590.50
Non Operating Income/Expense
66.80
91.50
65.60
42.70
Interest Expense
1.10
1.60
2.80
6
Pretax Income
1,145.70
1,559.00
1,657.00
3,244.70
Consolidated Net Income
1,145.70
1,559.00
1,657.00
3,244.70
Net Income
1,145.70
1,559.00
1,657.00
3,244.70
Net Income After Extraordinaries
1,145.70
1,559.00
1,657.00
3,244.70
Net Income Available to Common
1,145.70
1,559.00
1,657.00
3,244.70
EPS (Basic)
0.04
0.05
0.04
0.07
Basic Shares Outstanding
26,577.90
32,437.10
37,361.90
48,045.90
EPS (Diluted)
0.04
0.05
0.04
0.07
Diluted Shares Outstanding
26,577.90
32,437.10
37,361.90
48,045.90
EBITDA
994.20
1,381.70
1,499.50
2,492
Non-Operating Interest Income
3.00
2.70
4.10
33.50

About bioMmune Technologies

View Profile
Address
400 Burrard Street
Vancouver British Columbia V6C 3A6
Canada
Employees -
Website http://www.pascalbiosciences.com
Updated 07/08/2019
Pascal Biosciences Inc. is a biotechnology company, which engages in developing breakthrough treatments in the field of immuno-oncology. It focuses on the following technologies: Major Histocompatibility Complex I (MHC I), CD74 and Calcium Channel Blockers. The MHC I technology is a molecule that transports normal, abnormal and foreign protein fragments (peptides) to the surface of the cells where the fragments are then exposed to the immune system's T cells.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.